<DOC>
	<DOCNO>NCT00256776</DOCNO>
	<brief_summary>This international study adult patient diagnose multiple myeloma already receive least one autologous stem cell transplantation respond later progress , relapse , least one year transplantation . Eligible patient randomly assign one two treatment : either Velcade plus Thalidomide plus Dexamethasone Thalidomide plus Dexamethasone . Thalidomide Velcade two new agent recently become available treatment multiple myeloma , especially relapsed patient . This study therefore aim test hypothesis combination treatment Velcade plus Thalidomide plus Dexamethasone result long time progression ( measure time disease treat start get bad ) Thalidomide plus Dexamethasone alone .</brief_summary>
	<brief_title>MMVAR - Velcade : Study Velcade Treatment Myeloma Patients After Autologous Transplantation</brief_title>
	<detailed_description>Primary Objectives : * Test hypothesis treatment Velcade plus Thalidomide plus Dexamethasone combination , result long time progression ( TTP ) Thalidomide plus Dexamethasone subject relapse progressive myeloma autologous transplantation . Secondary Objectives : * Compare treatment group : overall survival ; response rate ( complete &amp; partial &amp; minimal ) use standard criterion treatment related complication . Study design methodology : This prospective , randomize , parallel-group , open-label phase III , intention treat , multicenter study . The main endpoint time-to-failure ( TTP=time progression ) . The power base initial assumption median TTP 1.5 year experimental ( Velcade ) group 1 year control group . The design study group sequential . There 4 interim analysis one final analysis . The study design priori 90 % power detect clinically relevant difference completion study 0.025 level . Patients multiple myeloma whose disease either progress relapse least one year one two autologous transplantation enrol . Prior random assignment , subject stratify center number autologous transplants.Subjects randomly assign treatment 1 : 1 allocation within stratum Velcade plus Thalidomide plus Dexamethasone ( VTD ) Thalidomide plus Dexamethasone . Velcade 1.3 mg/m2 give i.v . bolus Days 1 , 4 , 8 11 follow 10-day rest period ( Days 12 21 ) 8 cycle ( 6 month ) Days 1 , 8 , 15 , 22 follow 20-day rest period ( Days 23 42 ) 4 cycle ( 6 month ) . In arm , Thalidomide give 200 mg/day per o one year Dexamethasone 40 mg/day per o four day every three week one year.Treatment continue disease progression , occurrence unacceptable treatment-related toxicity , total 12 cycle Velcade except subject continue decrease level paraprotein 12 cycle . These subject may continue long treatment tolerate , continue respond . If subject CR , treatment continue least 2 cycle objective response confirm . For subject PR stable disease , treatment may continue maximum objective response confirm unless subject experience unacceptable treatment-related toxicity subject complete 12 cycle treatment . Disease assessment occur start cycle . If subject discontinues treatment without disease progression , disease assessment perform every 3 week 48-weeks start first dose study entry drug . Subjects progressed end 48-week follow period assess every 6 week disease progression document</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Male female ≥18 yearsofage Multiple myeloma evaluable disease Relapsing progressive disease Karnofsky performance status &gt; 50 % Life expectancy least 3 month Female childbearing potential must method birth control negative serum urine betahuman chorionic gonadotropin ( βHCG ) pregnancy test screening study Male must use contraception Voluntary write informed consent Nonsecretory multiple myeloma Platelet count &lt; 40,000 X 10^9/L Absolute neutrophil count &lt; 1.0 X 10^9/L Creatinine clearance &lt; 30 mL/minute Peripheral neuropathy &gt; = Grade 2 Seropositive HIV , active hepatitis A , B C infection Pregnant breastfeed female Patient hypersensitivity bortezomib , boron mannitol Other investigational drug Serious medical psychiatric illness Previous concurrent malignancy sit Poorly control hypertension , uncontrolled severe cardiovascular disease uncontrolled diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Velcade</keyword>
	<keyword>Autologous transplantation</keyword>
	<keyword>Relapse</keyword>
	<keyword>Disease progress</keyword>
</DOC>